Clinical Trial Update: Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 safety study evaluating different doses of hA20 (Veltuzumab) in CD20+ non-Hodgkin's lymphoma completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma Diffuse
• Non-hodgkin Lymphoma

Drugs mentioned

• hA20 (Veltuzumab) (veltuzumab)

Snippet

Sponsor: Gilead Sciences | Conditions: Non-Hodgkin's Lymphoma, Lymphoma, Diffuse | Phase 1, Phase 2 | Status: COMPLETED